Susceptibility of Influenza A (H3N2) Viruses to Neuraminidase Inhibitor Isolated during 2013–2017 in China's Mainland

HUANG Weijuan1 TAN Minju1 LI Xiyan1 CHENG Yanhui1 WEI Hejiang1 XIAO Ning1 ZHAO Xiang1 ZENG Xiaoxu1 WANG Dayan1

(1.Chinese National Influenza Center, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Key Laboratory for Medical Virology, National Health Commission, Beijing, China 102206)
【Novelty】The sensitivity of influenza A(H3N2) viruses to neuraminidase inhibitors that were prevalent in mainland China from 2013 to 2017 was first summarized in China, providing scientific basis for clinical use of antiviral drugs.

【Abstract】Antiviral-resistance data for 4 907 influenza A (H3N2) viruses isolated from 30 provinces (autonomous regions/municipalities) tested with aphenotypic method during 2013–2017 were analyzed to assess the susceptibility of influenza A (H3N2) viruses to neuraminidase inhibitors. All 4 907 influenza A (H3N2) viruses were sensitive to oseltamivir, although seven viruses (0.14%) exhibited reduced inhibition by zanamivir, among which six were detected in 2014. The IC50value tested was 24.03–49.21 folds greater than the reference IC50 value (0.28 nM). All six such viruses showed amino acid substitution of Q136K in the NA gene. In 2017, one virus showed mixed amino acid substitution of Q136Q/K in the NA gene, and the IC50 value tested was 10.90 folds greater than the reference IC50 value (0.31 nM). The seven viruses have been propagated in Madin-Darby canine kidney cells. Since the sequencing data for the original respiratory swab samples were not available, it cannot be excluded that the Q136K substitution arose in cell culture. These data indicated that circulating influenza A (H3N2) viruses in China's mainland form 2013 to 2017 retained susceptibility to neuraminidase inhibitors. This study provides a scientific basis for the use of clinical anti-influenza drugs.

【Keywords】 Influenza virus; A (H3N2) subtype; Neuraminidase inhibitor; Half-maximal inhibitory concentration; Susceptibility;


【Funds】 Emergency Prevention and Control Project of Ministry of Science and Technology (10600100000015001206)

Download this article


    [1] Skowronski D M, Masaro C, Kwindt T L, Mak A, Petric M, Li Y, Sebastian R, Chong M, De Serres G. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005–2006 season of dual A and B vaccine mismatch in Canada [J]. Vaccine, 2007, 25 (15): 2842–2851.

    [2] Xie H, Wan X F, Ye Z, Plant E P, Zhao Y, Xu Y, Li X, Finch C, Zhao N, Kawano T, Zoueva O, Chiang M J, Jing X, Lin Z, Zhang A, Zhu Y. H3N2 mismatch of 2014–15 northern hemisphere influenza vaccines and head-to-head comparison between human and ferret antisera derived antigenic maps [J]. Sci Rep, 2015, 5: 15279.

    [3] Hurt A C, Chotpitayasunondh T, Cox N J, Daniels R, Fry A M, Gubareva L V, Hayden F G, Hui D S, Hungnes O, Lackenby A, Lim W, Meijer A, Penn C, Tashiro M, Uyeki T M, Zambon M. Antiviral resistance during the 2009influenza A H1N1pandemic: Public health, laboratory, and clinical perspectives [J]. Lancet Infect Dis, 2012, 12 (3): 240–248.

    [4] Li T C, Chan M C, Lee N. Clinical implications of antiviral resistance in influenza [J]. Viruses, 2015, 7 (9): 4929–4944.

    [5] Gubareva L V, Besselaar T G, Daniels R S, Fry A, Gregory V, Huang W, Hurt A C, Jorguera P A, Lackenby A, Leang S K, Lo J, Pereyaslov D, Rebelo-de-Andrade H, Siqueira M M, Takashita E, Odagiri T, Wang D, Zhang W, Meijer A. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015–2016 [J]. Antiviral Res, 2017, 146: 12–20.

    [6] Kelso A, Hurt AC. The ongoing battle against influenza: drug-resistant influenza viruses: why fitness matters [J]. Nat Med, 2012, 18 (10): 1470–1471.

    [7] Butler J, Hooper K A, Petrie S, Lee R, Maurer-Stroh S, Reh L, Guarnaccia T, Baas C, Xue L, Vitesnik S, Leang S K, McVernon J, Kelso A, Barr I G, McCaw J M, Bloom J D, Hurt A C. Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A (H1N1) pdm09 influenza viruses [J/OL]. PLoS Pathog, 2014, 10 (4): e1004065.

    [8] Meetings of the WHO working group on surveillance of influenza antiviral susceptibility-Geneva November 2011and June 2012 [J]. Wkly Epidemiol Rec, 2012, 87 (39): 369–374.

    [9] Huang W J, Cheng Y H, Li X Y, Tan M J, Wei H J, Zhao X, Wang Z, Wang D Y, Shu Y L. Virological characteristics of influenza A (H3N2) virus strains isolated in China's mainland during 2014–2015 influenza surveillance year [J]. Chinese Journal of Microbiology and Immunology, 2016, 36 (1): 3–8 (in Chinese).

    [10] Chinese Center For Disease Control And Prevention. 中国流感监测周报 [EB/OL]. The first week of 2015-the 52nd week of 2017, (in Chinese).

    [11] Little K, Leang S K, Butler J, Baas C, Harrower B, Mosse J, Barr I G, Hurt A C. Zanamivir-resistant influenza viruses with Q136K or Q136R neuraminidase residue mutations can arise during MDCK cell culture creating challenges for antiviral susceptibility monitoring [J]. Euro Surveill, 2015, 20 (45) .

    [12] Lina B, Boucher C, Osterhaus A, Monto A S, Schutten M, Whitley R J, Nguyen-Van-Tam J S. Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study [J]. Influenza Other Respir Viruses, 2018, 12 (2): 267–278.

    [13] Oh D Y, Panozzo J, Vitesnik S, Farrukee R, Piedrafita D, Mosse J, Hurt A C. Selection of multi-drug resistant influenza A and B viruses under zanamivir pressure and their replication fitness in ferrets [J]. Antivir Ther, 2018, 23 (4): 295–306.

    [14] Yates P J, Raimonde D S, Zhao H H, Man CY, Steel H M, Mehta N, Peppercorn A F. Phenotypic and genotypic analysis of influenza viruses isolated from adult subjects during aphase II study of intravenous zanamivir in hospitalised subjects [J]. Antiviral Res, 2016, 134: 144–152.

    [15] Uyeki T M, Katz J M, Jernigan D B. Novel influenza A viruses and pandemic threats [J]. Lancet, 2017, 389 (10085): 2172–2174.

    [16] Quan C, Shi W, Yang Y, Yang Y, Liu X, Xu W, Li H, Li J, Wang Q, Tong Z, Wong G, Zhang C, Ma S, Ma Z, Fu G, Zhang Z, Huang Y, Song H, Yang L, Liu W J, Liu Y, Liu W, Gao G F, Bi Y. New threats from H7N9influenza virus:spread and evolution of high-and low-pathogenicity variants with high genomic diversity in wave five [J/OL]. J Virol, 2018, 92 (11): e00301–00318.

    [17] Sheu T G, Deyde V M, Okomo-Adhiambo M, Garten R J, Xu X, Bright R A, Butler E N, Wallis T R, Klimov A I, Gubareva L V. Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008 [J]. Antimicrob Agents Chemother, 2008, 52 (9): 3284–3292.

    [18] Bloom J D, Gong L I, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance [J]. Science, 2010, 328 (5983): 1272–1275.

    [19] Hurt A C, Hardie K, Wilson N J, Deng Y M, Osbourn M, Leang S K, Lee R T, Iannello P, Gehrig N, Shaw R, Wark P, Caldwell N, Givney R C, Xue L, Maurer-Stroh S, Dwyer D E, Wang B, Smith D W, Levy A, Booy R, Dixit R, Merritt T, Kelso A, Dalton C, Durrheim D, Barr IG. Characteristics of a widespread community cluster of H275Yoseltamivir-resistant A (H1N1) pdm09influenza in Australia [J]. J Infect Dis, 2012, 206 (2): 148–157.

    [20] Takashita E, Ejima M, Itoh R, Miura M, Ohnishi A, Nishimura H, Odagiri T, Tashiro M. A community cluster of influenza A (H1N1) pdm09virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013 [J]. Euro Surveill, 2014, 19 (1). pii: 20666.

    [21] Meijer A, Lackenby A, Hungnes O, Lina B, van-derWerf S, Schweiger B, Opp M, Paget J, van-deKassteele J, Hay A, Zambon M. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007–08season [J]. Emerg Infect Dis, 2009, 15 (4): 552–560.

    [22] Huang W, Li X, Cheng Y, Tan M, Guo J, Wei H, Zhao X, Lan Y, Xiao N, Wang D, Shu Y. Characteristics of oseltamivir-resistant influenza A (H1N1) pdm09virus during the 2013–2014 influenza season in China's mainland [J]. Virol J, 2015, 24:96.

    [23] Koszalka P, Tilmanis D, Hurt A C. Influenza antivirals currently in late-phase clinical trial [J]. Influenza Other Respir Viruses, 2017, 11 (3): 240–246.

This Article


CN: 11-1865/R

Vol 34, No. 06, Pages 793-799

November 2018


Article Outline



  • Materials and methods
  • Results
  • Discussion
  • References